Vascular Complications in Children From T1D Diagnosis
NCT05790785
Recruiting
Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
04/29/2025
Locations: Endocrine and Diabetes Unit, BC Children's Hospital, Vancouver, British Columbia
Conditions: Type 1 Diabetes, Cardiovascular Complications, Child, Adolescent
Register for Updates
Transcutaneous Electrical Stimulation for Apnea Detected by Capnography
NCT06823661
Recruiting
After surgery, patients often recover in a special area called the Post Anesthesia Care Unit (PACU). Patients may receive pain medications either during the surgery or afterward in the PACU. While these medications are important for controlling pain, some of them can slow down breathing. To ensure patients' breathing remains safe, the nurses in the PACU monitor respiratory rate (how many breaths a patient takes per minute) and oxygen levels using standard monitoring equipment. This is the usual... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Toronto General Hospital, Toronto, Ontario +1 locations
Conditions: Respiratory Depression, Opioids
Register for Updates
Study of BLU-808 in Allergic Rhinoconjunctivitis
NCT06922448
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Red Maple Trials, Ottawa, Not set
Conditions: Allergic Rhinoconjunctivitis
Register for Updates
MitraClip REPAIR MR Study
NCT04198870
Recruiting
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: University Hospital - Univiversity of Alabama at Birmingham, Birmingham, Alabama +84 locations
Conditions: Mitral Valve Regurgitation
Register for Updates
Ferric Citrate and Chronic Kidney Disease in Children
NCT04741646
Recruiting
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20... Read More
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
04/29/2025
Locations: University of California, Los Angeles, Los Angeles, California +19 locations
Conditions: Chronic Kidney Diseases
Register for Updates
Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia
NCT06281756
Recruiting
Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: National Jewish Health, Denver, Colorado +3 locations
Conditions: Insomnia, Insomnia Chronic, Insomnia, Primary, Blood Pressure, Blood Pressure, High
Register for Updates
Characterization of Chronic Hand Eczema
NCT05026554
Recruiting
Prospective longitudinal study to characterize Choronic Hand Eczema (CHE) subtypes and Atopic Dermatitis (AD) with noninvasive molecular and imaging techniques, and assess changes through time and its association with quality of life.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/29/2025
Locations: Innovaderm Research, Montreal, Quebec
Conditions: Chronic Hand Eczema, Atopic Dermatitis
Register for Updates
Safety of ENC-201-CED ENCRT
NCT06408311
Recruiting
The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/29/2025
Locations: UHN, Toronto, Ontario +1 locations
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Anxiolysis for Laceration Repair in Children
NCT05383495
Recruiting
This is a 3-arm adaptive clinical trial to the optimal light sedative for reducing distress during laceration repair in children. The investigators will compare intranasal (IN) dexmedetomidine, IN midazolam, and nitrous oxide (N20). The primary outcome is the Observational Scale of Behavioral Distress - Revised (OSBD-R).
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
04/29/2025
Locations: London Health Sciences Centre, London, Ontario
Conditions: Laceration of Skin, Distress, Emotional
Register for Updates
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
NCT05615623
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
04/28/2025
Locations: Sunnybrook Research Institute, Toronto, Ontario
Conditions: Brain Tumor
Register for Updates
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +18 locations
Conditions: Multiple Myeloma
Register for Updates
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Birmingham, Alabama +39 locations
Conditions: Generalized Myasthenia Gravis
Register for Updates